CN1813885A - 复方丹参喷雾剂及其制备方法 - Google Patents
复方丹参喷雾剂及其制备方法 Download PDFInfo
- Publication number
- CN1813885A CN1813885A CN 200510104934 CN200510104934A CN1813885A CN 1813885 A CN1813885 A CN 1813885A CN 200510104934 CN200510104934 CN 200510104934 CN 200510104934 A CN200510104934 A CN 200510104934A CN 1813885 A CN1813885 A CN 1813885A
- Authority
- CN
- China
- Prior art keywords
- salviae miltiorrhizae
- filtrate
- solution
- ethanol
- fine powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007921 spray Substances 0.000 title claims abstract description 34
- 150000001875 compounds Chemical class 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title claims description 21
- 240000007164 Salvia officinalis Species 0.000 title claims description 15
- 235000005412 red sage Nutrition 0.000 title claims description 15
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 30
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 30
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 23
- 238000002360 preparation method Methods 0.000 claims abstract description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 107
- 239000000706 filtrate Substances 0.000 claims description 44
- 239000000284 extract Substances 0.000 claims description 36
- 239000000843 powder Substances 0.000 claims description 33
- 238000012360 testing method Methods 0.000 claims description 29
- 238000010992 reflux Methods 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000013558 reference substance Substances 0.000 claims description 22
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 claims description 20
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 239000000047 product Substances 0.000 claims description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 239000004615 ingredient Substances 0.000 claims description 15
- 238000004064 recycling Methods 0.000 claims description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 238000005303 weighing Methods 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 239000000853 adhesive Substances 0.000 claims description 6
- 230000001070 adhesive effect Effects 0.000 claims description 6
- 239000003208 petroleum Substances 0.000 claims description 6
- 239000000741 silica gel Substances 0.000 claims description 6
- 229910002027 silica gel Inorganic materials 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 238000004809 thin layer chromatography Methods 0.000 claims description 6
- -1 and filter Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 229960000583 acetic acid Drugs 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000012362 glacial acetic acid Substances 0.000 claims description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 4
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 4
- 229930182490 saponin Natural products 0.000 claims description 4
- 150000007949 saponins Chemical class 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000013355 food flavoring agent Nutrition 0.000 claims description 3
- 238000003908 quality control method Methods 0.000 claims description 3
- 230000000274 adsorptive effect Effects 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 238000012850 discrimination method Methods 0.000 claims description 2
- 239000003480 eluent Substances 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical class O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 2
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 claims description 2
- XYKIUTSFQGXHOW-UHFFFAOYSA-N propan-2-one;toluene Chemical compound CC(C)=O.CC1=CC=CC=C1 XYKIUTSFQGXHOW-UHFFFAOYSA-N 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 claims description 2
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 claims description 2
- 235000012141 vanillin Nutrition 0.000 claims description 2
- 229930183118 Tanshinone Natural products 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 45
- 208000029078 coronary artery disease Diseases 0.000 abstract description 6
- 241001072909 Salvia Species 0.000 abstract 2
- 235000017276 Salvia Nutrition 0.000 abstract 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 239000009724 Salvia extract Substances 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 239000000443 aerosol Substances 0.000 description 31
- 230000000694 effects Effects 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- 239000003814 drug Substances 0.000 description 23
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 16
- 239000003826 tablet Substances 0.000 description 15
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 14
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 14
- 208000002193 Pain Diseases 0.000 description 13
- 239000008899 fufang danshen Substances 0.000 description 11
- 208000031225 myocardial ischemia Diseases 0.000 description 11
- 208000028867 ischemia Diseases 0.000 description 10
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 210000000038 chest Anatomy 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 210000004204 blood vessel Anatomy 0.000 description 6
- 239000007935 oral tablet Substances 0.000 description 6
- 229940096978 oral tablet Drugs 0.000 description 6
- 206010008479 Chest Pain Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 206010014080 Ecchymosis Diseases 0.000 description 4
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229960003711 glyceryl trinitrate Drugs 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 239000000006 Nitroglycerin Substances 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 2
- 206010012118 Defect conduction intraventricular Diseases 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- 229930194542 Keto Natural products 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 206010003671 Atrioventricular Block Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041956 Stasis syndrome Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000005634 blind loop syndrome Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960001317 isoprenaline Drugs 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000011003 system suitability test Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
组别与剂量 | 动物数 | iv垂体后叶素第一期发生缺血情况 | 第二期发生缺血情况 | ||
T波缺血改变(%) | ST段缺血改变(%) | T波缺血改变(%) | ST段缺血改变(%) | ||
氟里昂酒精对照组20次/kg | 8 | 75~51% | 179.6~108.8% | 66.7~33.3% | 126.1~85。5% |
复方丹参片剂2.7g/kg | 8 | 23~9%·· | 82.4~54.4% | 31.4~5% | 43.2~26%·· |
复方丹参气雾剂0.44g/kg | 8 | 39~13%· | 71.7~36.3%· | 11.3~0%· | 68.2~34%· |
复方丹参气雾剂0.22g/kg | 8 | 69~23% | 106.2~72.6% | 47.5~21.9% | 34.8~9%·· |
组别与剂量 | 动物数 | 给药前( X±SEmv) | iv垂体后( X±SEmv) | 喷药后( X±SEmv) | |||
T波 | S-T段 | T波 | S-T段 | T波 | S-T段 | ||
氟利昂酒精对照组 | 10 | 0.14±0.05 | 0.26±0.06 | 0.16±0.06 | 0.57±0.07 | 0.12±0.049 | 0.41±0.08 |
气雾剂组0.44g/kg | 10 | 0.15±0.03 | 0.24±0.03 | 0.13±0.03 | 0.60±0.08 | 0.10±0.03 | 0.19±0.04 |
口服片剂组2.7g/kg | 10 | 0.13±0.06 | 0.29±0.07 | 0.13±0.06 | 0.51±0.12 | 0.18±0.07 | 0.33±0.07 |
组别与剂量 | 动物数 | T波值( X±SEmv) | 升高(%) | ||
给药前 | iv垂体后叶素 | 喷药治疗后 | |||
氟利昂酒精对照组20次/kg气雾剂组0.14g/kg口服片剂组0.9g/kg | 666 | 0.17±0.030.20±0.020.19±0.03 | 0.29±0.050.31±0.040.296±0.04 | 0.26±0.030.20±0.040.22±0.04 | 152.9%100%115.8% |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005101049340A CN100364566C (zh) | 2005-09-22 | 2005-09-22 | 复方丹参喷雾剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005101049340A CN100364566C (zh) | 2005-09-22 | 2005-09-22 | 复方丹参喷雾剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1813885A true CN1813885A (zh) | 2006-08-09 |
CN100364566C CN100364566C (zh) | 2008-01-30 |
Family
ID=36906317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005101049340A Active CN100364566C (zh) | 2005-09-22 | 2005-09-22 | 复方丹参喷雾剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100364566C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102145044A (zh) * | 2011-04-18 | 2011-08-10 | 天圣制药集团股份有限公司 | 一种治疗心脑血管疾病的复方喷雾剂及其制备方法 |
CN110702822A (zh) * | 2019-02-25 | 2020-01-17 | 广州白云山医药集团股份有限公司白云山何济公制药厂 | 田七跌打风湿软膏中三七含量的检测方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1502341A (zh) * | 2002-11-22 | 2004-06-09 | 李雪晶 | 一种中药新制剂——复方丹参分散片的制备方法 |
-
2005
- 2005-09-22 CN CNB2005101049340A patent/CN100364566C/zh active Active
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102145044A (zh) * | 2011-04-18 | 2011-08-10 | 天圣制药集团股份有限公司 | 一种治疗心脑血管疾病的复方喷雾剂及其制备方法 |
CN110702822A (zh) * | 2019-02-25 | 2020-01-17 | 广州白云山医药集团股份有限公司白云山何济公制药厂 | 田七跌打风湿软膏中三七含量的检测方法 |
CN110702822B (zh) * | 2019-02-25 | 2020-08-04 | 广州白云山医药集团股份有限公司白云山何济公制药厂 | 田七跌打风湿软膏中三七含量的检测方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100364566C (zh) | 2008-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1861146A (zh) | 一种复方血栓通软胶囊及其制备方法 | |
CN101040906A (zh) | 一种治疗心脑血管疾病的注射剂及其制备方法和质控方法 | |
CN100364566C (zh) | 复方丹参喷雾剂及其制备方法 | |
CN1164264C (zh) | 三七总皂苷分散片及其制备方法 | |
CN1850167A (zh) | 一种消渴降糖滴丸及其制备方法 | |
CN1297279C (zh) | 一种含丹参素、三七总皂苷和冰片的药物组合物及其制备和应用 | |
CN1843461A (zh) | 一种中药组合物及其制备方法和质量控制方法 | |
CN101028387A (zh) | 一种治疗慢性***炎的口服固体制剂及其制备方法 | |
CN1264506C (zh) | 一种丹参素的药物组合物的制备方法 | |
CN1582952A (zh) | 积雪草总苷在制备防治心、脑血管疾病药物中的用途 | |
CN101073598A (zh) | 一种治疗心脑血管病的药物组合物及其制剂 | |
CN102702061B (zh) | 一种盐酸水苏碱化合物及含有该化合物的药物组合物 | |
CN1282468C (zh) | 中药脑得生软胶囊及其制备方法 | |
CN102755517B (zh) | 一种治疗心律失常的中药贴剂及其制备方法 | |
CN1081465C (zh) | 一种治疗冠心病心绞痛的红景天注射剂的制备方法 | |
CN1583102A (zh) | 一种治疗妇科血瘀症疾病的药物的制备方法 | |
CN1259934C (zh) | 一种用于治疗心血管疾病的山楂叶注射剂 | |
CN100337654C (zh) | 一种治疗心血管疾病的中药有效组分的组合物 | |
CN1785240A (zh) | 一种用于治疗冠心脏病类的滴丸剂及其制备方法 | |
CN1634509A (zh) | 一种治疗疼痛的伊痛舒滴丸及其制备方法 | |
CN1251717C (zh) | 一种治疗冠心病心绞痛的中药组合物 | |
CN102920808B (zh) | 一种治疗动脉硬化、冠心病的中药制剂及其制备方法 | |
CN1733091B (zh) | 精制冠心控释制剂及其制备方法 | |
CN1919244A (zh) | 一种治疗心血管疾病的中药 | |
CN100546589C (zh) | 虫草头孢菌粉抗心律失常有效部位的制备及其药物制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Tonghua Baishan Pharmaceutical Ltd Assignor: Hua Yuqiang Contract record no.: 2011220000002 Denomination of invention: Compound red sage root spray and its preparing method Granted publication date: 20080130 License type: Exclusive License Open date: 20060809 Record date: 20110104 |
|
TR01 | Transfer of patent right |
Effective date of registration: 20170424 Address after: 134100 Tonghua, Sichuan Province, Tonghua Qu Chuan Development Zone, Jilin Patentee after: Tonghua Baishan Pharmaceutical Ltd Address before: 134100 Tonghua province unity Road, Jilin, No. 3333 Patentee before: Hua Yuqiang |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211019 Address after: 134100 Liming Industrial Zone, kuaimao Town, Tonghua County, Tonghua City, Jilin Province Patentee after: TONGHUA HUAXIA PHARMACEUTICAL Co.,Ltd. Address before: 134100 Tonghua Wanchuan Development Zone, Tonghua County, Jilin Province Patentee before: TONGHUA BAISHAN PHARMACEUTICAL Ltd. |
|
TR01 | Transfer of patent right |